Amplifica AMP 303 Trial Results

Amplifica Reveals Results from Its First-in-Human Trial For Androgenic Alopecia

September 30, 2024 /

Amplifica, a clinical-stage biopharmaceutical company based in San Diego, has announced the results from its first-in-human trial of AMP-303, an intradermal injection treatment for androgenic alopecia (AGA). Amplifica has several AGA treatments in the pipeline, including AMP-203 (osteopontin) and AMP-601 (SCUBE3). What is AMP-303? We spoke about AMP-303 last year when they announced the initiation…

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.